Literature DB >> 1691412

Renal effects of converting enzyme inhibitors in hypertension and diabetes.

S Anderson1.   

Abstract

Recent studies in animal models suggest that glomerular capillary hyperperfusion and hypertension, rather than ischemia, cause renal injury. Interventions that control glomerular capillary hypertension may protect against progressive injury, even in the presence of continued systemic hypertension. In the absence of systemic hypertension, diabetes mellitus is a prominent clinical example of glomerular hypertension. Animal studies have shown that glomerular hemodynamic abnormalities, especially elevations in glomerular pressure, play an important role in the pathogenesis of diabetic glomerulopathy. A number of clinical observations suggest that angiotensin converting enzyme (ACE) inhibitors may delay the progression of diabetic nephropathy by their effects on renal hemodynamics. In experimental animals, comparisons between calcium channel blockers and ACE inhibitors have shown the latter to be more effective in protecting the kidneys. Preliminary clinical studies indicate that ACE inhibitors may have advantages in preserving renal function in hypertensive and diabetic patients with renal failure.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1691412     DOI: 10.1097/00005344-199000153-00003

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  3 in total

Review 1.  Chemoprophylaxis of diabetic nephropathy in the elderly.

Authors:  E Jungmann
Journal:  Drugs Aging       Date:  1996-12       Impact factor: 3.923

Review 2.  Renal long-term effects of calcium antagonist treatment in patients with diabetes mellitus.

Authors:  E Jungmann; K H Usadel
Journal:  Clin Investig       Date:  1992-10

3.  Effects of calcium channel blockers on proteinuria in patients with diabetic nephropathy.

Authors:  Robert D Toto; Min Tian; Kaffa Fakouhi; Annette Champion; Peter Bacher
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-10       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.